tickstock newsroom AI
Articles
City broker raises IQE price target to 50p, keeps Hold
Panmure Liberum still sees IQE as a 'Hold', but upgraded its price target to 50p from 40p, following MACOM’s strategic investment.
Analyst says Bloomsbury Publishing results support confidence, upgrades price target
DB raises its price target to 760p from 700p, and repeated a Buy rating following the publisher's FY26 results.
Itaconix shares climbs as it enters partnership for plant-based paint products
The London-listed small-cap has partnered with an established specialty paint company to finish and evaluate initial plant-based paint formulations and has filed both a patent application and a trademark application for the new product class.
Europa Oil & Gas shares rise after EG-08 farm-out approval
Antler, 42.9% owned by Europa Oil & Gas, has secured Ministry for Mining and Hydrocarbons Department approval for a farm-out to Fuhai that will leave Antler with a 40% working interest and operator role in the EG-08 PSC.
Pulsar Helium shares surge thanks to Topaz acreage expansion
It has paid US$2.48m in cash to acquire roughly 1,360 acres of surface land at its Topaz Project in Minnesota, gaining direct ownership of the area that includes its Jetstream #7 well.
Ocado Group shares boosted by Asda partnership
CelLBxHealth shares rocket on AstraZeneca master services agreement
Small Caps Today: CelLBxHealth signs AstraZeneca services deal, Europa Oil & Gas, Tooru, Fandango, Itaconix, MedPal A and more
A landmark commercial validation headlined Friday's small-cap session, with CelLBxHealth surging nearly 46% after landing a Master Services Agreement with AstraZeneca, one of the most significant partnership announcements in the AIM biotech space this year. Elsewhere, corporate activity ranged from
European Opportunities Trust proposes rollover into JEGI or new Liontrust fund
Avacta names Richard Hughes as non‑executive chairman
Kavango Resources appoints interim CEO and new CFO
Time Out Group expands foodhall operation with Time Out Market Vancouver
The publisher-come-foodie-destination-business has now opened Time Out Market Vancouver, a 51,000 sq ft food and cultural market.
Blencowe upgrades the economics of Orom-Cross graphite project
The junior mining firm has updated its Definitive Feasibility Study for the Orom-Cross graphite project, lifting NPV10 to US$1.254bn, and increasing life-of-mine free cash to US$4.466bn. Meanwhile, Phase 1 and Phase 2 capex estimates remain unchanged.
The Smarter Web Company buys more Bitcoin
The web services and digital asset advocate bought nine additional Bitcoin at an average price of £54,771 each.
Dianomi says it returned to profitability as FY revenue held up
The content marketing platform reported revenue of £27.4m for the year, down 2.1% on 2024, but said it returned to growth and profitability in the second half.
Serabi Gold more than doubles Q1 EBITDA and becomes debt-free
The miner reported Q1 2026 EBITDA of $29.2m, up from $12.4m a year earlier, delivering a post-tax profit of $21m and raising cash to $64.4m after repaying its Santander loan.
MedPal AI posts first revenues as pharmacy run rate tops £5m
The company reported £1.60m of revenue for the six months to 28 February, moving from a pre-revenue position whilst investing heavily, and recording a loss after tax of £3.27m.
Fandango signs agreement for potential Idaho silver acquisition
It has executed a non-binding Heads of Terms for a potential interest in an Idaho silver property and appointed David Facey as a Non-Executive Director with immediate effect.
Talisman Metals reports high‑grade copper channel samples at Tirzzit
Channel sampling at its newly acquired Tirzzit Cu‑Ag project returned a best intercept of 2.65m at 1.71% Cu and 22.25ppm and demonstrated seven of seven channels above a 0.3% Cu cut‑off over 700m of strike within an interpreted 4.6km trend.
The Premarket Brief: CelLBxHealth signs AstraZeneca services deal, Tooru, Clean Power Hydrogen, Ocado
A Master Services Agreement with AstraZeneca headlines Friday morning's small-cap news, with CelLBxHealth named as a qualified clinical-trial service provider to the pharma giant.